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Abstract
Background Esophageal stricture is one of the serious
adverse events following endoscopic submucosal dissec-
tion (ESD). However, optimum preventive techniques are
still lacking.
Aims Our primary objective was to evaluate the incidence
of post-ESD esophageal stricture with the application of
carboxymethyl cellulose (CMC) sheets. Secondary objec-
tives were to determine the number of sessions of endo-
scopic balloon dilatation (EBD) required to resolve post-
ESD strictures and the incidence rate of peri-operative
adverse events.
Methods This was a pilot, single-center, prospective
study. Seven patients who had high risks of developing
post-ESD esophageal stricture were enrolled into our study.
CMC sheets were applied to the mucosal defects
immediately after the completion of ESD. Patients were
monitored and reviewed after ESD to detect any adverse
events.
Results The incidence rate of post-operative stricture was
57 % (4/7 patients). Among patients who required EBD,
the number of sessions performed was 2.8 ± 2.2. No
serious post-operative adverse events were reported.
Conclusion The use of CMC sheets appears to be a safe
and effective prophylactic treatment for esophageal stric-
ture following extensive ESD.
Keywords Carboxymethyl cellulose  Esophagus 
Endoscopy  Dissection
Introduction
ESD for Treatment of Early Esophageal Neoplasm
The application of endoscopic mucosal resection (EMR)
and endoscopic submucosal dissection (ESD) techniques in
the treatment of early esophageal neoplasm are well
known. ESD has an advantage over EMR for removing
tumors en bloc, regardless of their size [1, 2]. ESD also
permits a thorough histological assessment of the speci-
mens removed in one piece with tumor-free lateral or basal
margins. This will avoid any residual disease and local
recurrence [2, 3].
Complications of ESD
Several studies have reported multiple substantial risk of
ESD-related complications, which includes potentially life-
threatening perforation and post-procedural stenosis [4, 5].
The occurrence of stricture can cause dysphagia and may
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severely impair patients’ quality of life (QOL). The exact
incidence rate of post-ESD esophageal stricture remains
obscure. However, reports show that cervical location, a
tumor size greater than 3/4 of the esophageal circumfer-
ence, and a longitudinal tumor diameter of more than
40 mm are associated with higher risk of post-procedural
stricture [6]. In particular, the incidence rate of stricture is
known to significantly increase in proportion to the overall
size of the target lesion and the circumferential size of the
post-ESD mucosal defect [7].
Treatment and Prevention of Post-ESD Esophageal
Stricture
Multiple strategies and methods had been proposed and
investigated for prevention of post-ESD esophageal stric-
ture [8]. Although endoscopic balloon dilatation (EBD) has
been a treatment of choice in the setting of benign eso-
phageal strictures, it still carries the risk of perforation [9].
Currently, multiple sessional EBD is recommended for
prevention of post-ESD esophageal stricture [10]. How-
ever, this involves high cost with additional risk of
perforations.
There is also a role of an anti-inflammatory approach to
prevent post-ESD esophageal stricture. Some authors have
advocated the use of endoscopic intralesional injections of
steroids or systemic steroids. However, these carry the risks
of delayed wound healing, ulcer formation and metabolic
disturbance (hyperglycemia and osteoporosis) [11, 12].
Other agents includes N-acetylcysteine and mitomycin
C with their antifibrotic effects but preliminary data
showing their efficacy are still lacking [13–15]. Sakaguchi
et al. [16] also reported a small pilot study demonstrating
the efficacy of polyglycolic acid (PGA) sheets with fibrin
glue to prevent post-ESD stricture.
In general, there is still a need to explore a better and
efficient way to prevent post-ESD esophageal stricture.
Material Used in the Trial and Its Rationale
Bioresorbable membrane consisting of hyaluronic acid and
carboxymethyl cellulose (CMC) has gained regulatory
approval for clinical use in both general and gynecological
surgery following demonstration of efficacy and safety in
reducing adhesions [17–19].
TiSTAT S-100 (CMC hemostatic sheet, 5 cm 9 8 cm;
by Beijing Textile Science Research Institute, Beijing;
China food and drug administration number: 3640430)
(Fig. 1a, b) is a biodegradable suture material and its
potential as a method to reinforce the suture and minimize
scar contracture in medical fields has been demonstrated
[20–22]. The main mechanics for inhibition of scar
formation includes: (1) formation of a bio-physical barrier
on the wound, (2) rapid clotting effect, via forming an
adhesive plug compressing the vessels, activating clotting
factors and accumulating platelets, (3) inhibition of
fibroblast and human fibrinogen, (4) production of hya-
luronic acid, and (5) promotion of epithelial cell growth
[23].
TiSTAT S-100 achieved Food and Drug Administration
(FDA) approval in 2007 and obtained the European CE
mark in 2009. It consists of 100 % natural, plant-derived
cellulose and can be completely absorbed via hydrolysis
within 7–14 days. It has a high degree of biocompatibility
with no known reports of rejection. However, there are no
reports evaluating the efficacy of this material in prevent-
ing post-ESD stricture.
Patients and Methods
This was a pilot, single-center, prospective study. Appli-
cation of CMC sheets after ESD was begun only after
approval from the Research Ethics Committee of the Sec-
ond Military University, Changhai Hospital.
Between April and September 2015, we enrolled sub-
jects into our study who were referred for further treatment
of superficial esophageal cancer. Only patients with an
elevated baseline risk for developing post-ESD esophageal
stricture were recruited. They were selected if they met one
or more of the following criteria: cervical location (the area
extending from the pharyngoesophageal junction to the
suprasternal notch); a tumor size greater than 1/2 of the
esophageal circumference (the size of mucosal defect
greater than 3/4 of esophageal circumference); or a longi-
tudinal tumor diameter of more than 40 mm (Fig. 2).
Contraindications to the use of CMC sheets are almost non-
existent. This includes patients who have anaphylaxis to
components of CMC. We also excluded patients who had
contraindications for ESD, such as: suspected invasion into
or beyond the deep submucosal layer after diagnostic
work-up (CT2sm carcinoma); uncooperative patients;
patients who cannot provide informed consent; severe or
uncontrollable coagulopathy; and patients with substantial
comorbidity and limited life-expectancy.
All subjects submitted written forms of informed con-
sent for the application of CMC sheets in addition to giving
consent for esophageal ESD according to normal clinical
practice.
Endoscopic Submucosal Dissection Procedure
A single-channel upper gastrointestinal endoscope (GIF
Q260J; Olympus) with a transparent cap (D-201-10704;
Olympus) attached to its tip and a high frequency generator
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VIO 300D (ERBE; Elektromedizin, Tu¨bingen, Germany)
were used during ESD. All ESDs were performed at
Changhai Hospital according to methods described in a
previous study [24]. In brief, close observation of the tar-
geted esophageal lesions was done using narrow band
imaging (NBI) and chromoendoscopy with 2 % Lugol’s
solution staining (Fig. 3a), followed by marking of the
margin of the lesion using the Dual Knife (KD-630L;
Olympus). The lesion was injected submucosally using a
solution of 250 ml glycerin fructose/sodium chloride, 2 mg
adrenaline, and 2 ml indigo carmine to elevate the lesion.
The lesion was then incised and dissected using the Dual
Knife/Insulated-tip Knife-2 (KD-611 L; Olympus) until
ESD was completed (Fig. 3b).
CMC Sheet Deployment
Immediately after ESD had been completed, CMC sheets
were prepared by cutting into multiple small pieces (each
measuring approximately 10 9 20 mm) (Fig. 3c) (Video).
The transparent cap was switched to a cap with a longer
distal tip (MH-463/MH-594; Olympus) in order to
accommodate the sheet. After the CMC sheet had been
grasped with endoscopic forceps, it was pulled into the cap
(Fig. 3d) which was then inserted orally to the site of the
post-ESD defect. The sheet was released onto the surface
of post-ESD mucosal defect by releasing the forceps
(Fig. 3e). The sheet adhered to the mucosal defect once it
was exposed to the moist surface of the defect. This process
was repeated until the defect was fully covered by the
sheets (Fig. 3f).
Peri-operative Management
On the day before ESD, patients were kept nil by mouth
after their evening meal, and given intravenous fluid. Fol-
lowing ESD, Pantoprazole was given intravenously (40 mg
twice a day) for the first 48 h. Oral pantoprazole (40 mg
daily) was prescribed for 1 month after discharge. Routine
laboratory investigations along with chest and abdominal
radiographs were performed. Clear fluids and then soft
diets were introduced in a gradual manner. Scheduled post-
operative endoscopies were performed on days 7 and 28
after ESD, or at any time if patients developed dysphagia.
If the patients did not show up for post-operative endo-
scopies, phone calls were made to evaluate patients’
symptoms.
Definition of Post-operative Stricture
Post-operative stricture was determined by the presence of
stenosis of the esophageal lumen in which a 9.8-mm-di-
ameter upper gastrointestinal endoscope (GIF Q240 or GIF
H260; Olympus) was unable to pass through it or the
Fig. 1 Carboxymethyl cellulose sheets used as a study material
Endoscopic submucosal dissection (ESD) for early esophageal 
neoplasia performed between April and September 2015.(n=116)
Included:
1. Tumor at cervical location
2. Post-ESD mucosal defect >3/4 of esophageal 
circumference
3. Longitudinal tumor diameter >40mm
Excluded:
1. Those who had anaphylaxis towards 
CMC(n=0)
2. Those who were lost on follow-up (n=1)
Patients recruited and treated with CMC sheets after ESD. 
(n=8)
Included in per protocol analysis (n=7)
Fig. 2 Flow diagram of the recruited subjects
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presence of dysphagia. The day of stricture occurrence was
defined as the day when the stricture was endoscopically
confirmed.
Endoscopic Balloon Dilation
In patients who developed an esophageal stricture, EBD
was carried out using an esophageal balloon dilation
catheter (EclipseTM TTC wire-guided balloon dilator
12 mm/14 mm/16 mm; Cook Medical, USA) or Savary-
Gilliard wire-guided polyvinyl dilators. EBD was repeated
as required until the esophageal stenosis widened and it
was possible to pass the endoscope through the esophageal
lumen. Patients continued their endoscopic follow-up for a
minimum of 4 weeks when the stricture had subsided.
Follow-Up Endpoints
The primary objective of this study was to evaluate the
incidence of post-ESD esophageal stricture with the
application of CMC sheet. Secondary objectives were the
number of sessions of EBD required to resolve any sub-
sequent strictures. We also explored the feasibility and
timing of deploying CMC sheet. Lastly, we evaluated the
incidence rate of post-operative adverse events that were
potentially attributable to the procedure and study material.
Results
Seven patients fulfilled the inclusion criteria and were
recruited into our study between April and September
2015. Patient baseline characteristics are summarized in
Table 1.
All our patients presented with esophageal lesion(s) and
left with a mucosal defect comprising 3/4 or more of
esophageal circumference after ESD. En bloc esophageal
ESD with tumor-free vertical and lateral margins were
performed successfully in all subjects. There were no major
intra-/post-operative adverse events, such as massive/de-
layed bleeding, signs of perforation, anaphylactic reaction,
severe chest pain, cardiovascular events or death. Three
patients developed low-grade fever while hospitalized after
ESD. They were treated conservatively and discharged
when well.
CMC sheets were all deployed successfully in all cases
with a mean time of 12.6 ± 4.0 min (Table 2). Each
patient required only one CMC sheet, which was cut and
divided into 8–10 smaller pieces to facilitate deployment.
Three patients had an endoscopically visible residual CMC
matrix after 1 week and they did not require any EBD
sessions during follow-up. The overall incidence rate of
post-operative stricture was 57 % (4/7 patients). Among
patients who required EBD, the number of sessions per-
formed was 2.8 ± 2.2. No post-operative adverse events
were reported.
Discussion
Post-ESD esophageal stricture is a major concern among
patients who undergo near or full circumferential esophageal
ESD. Beside prophylactic EBD sessions, current popular
practice to prevent post-ESD esophageal stricture includes
systemic and local injection of corticosteroids [8, 11, 12].
The incidence of esophageal stenosis following ESD is
reported to be 75–92 % [13]. This incidence is reduced with
prophylactic EBD sessions (59 %), intralesional injections
Fig. 3 The management of a
study subject. a An extensive
early esophageal neoplasm
viewed using chromoendoscopy




c Preparation of carboxymethyl
cellulose (CMC) sheets. d CMC
sheet pulled into the cap with a
biopsy forcep. e Application of
CMC sheets. f Defect
appearance immediately after
CMC sheets placement
1766 Dig Dis Sci (2016) 61:1763–1769
123
of steroids (19 %) and systemic steroid (5.3 %) [11, 12, 14].
However, the use of steroids has been linked to certain
morbidity such as systemic infection and post-operative
perforation. There were also limited data showing the effi-
cacy of anti-fibrotic agents such as N-acetylcysteine, mito-
mycin-C and PGA sheets [13–16]. Some clinical trials
explored the potential of newer therapies such as scaffold-
based and cell-based treatments, but their clinical evidence
was still lacking [25–27]. Another recent clinical study also
demonstrated the efficacy of viscous budesonide slurry in
reducing post-esophageal stricture (37 % as compared to
control group, 13.8 %, p\ 0.05) among patients undergoing
complete endoscopic resection for dysplastic Barrett’s
esophagus and early esophageal adenocarcinoma [28].
Our study revealed that CMC sheet application was
effective in reducing the incidence of post-ESD esopha-
geal stricture. This was evidenced by the fact that the
total number of EBD required was reduced among
patients who had high risks of developing a stricture. Our
results (mean EBD post-esophageal ESD was 2.8) were
fairly comparable with other studies using oral adminis-
tration of corticosteroids (mean EBD post-ESD was
reported to be 1.7) and focal triamcinolone injection
(mean EBDs required were reported as 1.7 and 6.1) [12,
14, 29]. The best result thus far was the use of PGA sheet
which reported a mean EBD of 0.8 [16]. However, all the
clinical trials involved a small number of subjects, rang-
ing from 8 to 40.
The application of CMC sheet is technically feasible and
easy, requiring a single operator. The average amount of
time to apply is fairly short, mean 12.6 ± 4.0 min. This
seemed acceptable in our clinical practice considering that
multiple extra sessions of EBD would consume more time
and cost (previous reports revealed mean EBD ranging
Table 1 Baseline
characteristics of seven subjects
who underwent ESD for
esophageal tumors in our study
Patient sex (men:women) 3:4
Patient age, mean ± SD (years) 62.4 ± 4.7
Tumor location (%)
Cervical 0 (0)
Upper thoracic 2 (28.6)
Mid-thoracic 5 (71.4)
Lower thoracic 0 (0)
Tumor depth (%)
Confined to the epithelium 0 (0)
Confined to the lamina propria mucosa 0 (0)
Confined to the muscularis mucosa 6 (85.7)
Sm1 (invading the submucosa B 200 lm) 1 (14.3)
Sm2 (invading the submucosa[ 200 lm) 0 (0)
Tumor size, mean ± SD (mm) 44.7 ± 14.4 (7 patients)
Size of mucosal defect post-ESD (%)
At least 3/4 esophageal circumference 5 (71.4)
Full esophageal circumference 2 (28.6)
SD standard deviation, Sm submucosa, ESD endoscopic submucosal dissection
Table 2 Details of ESD and
CMC sheet application
procedures, adverse events, and
their subsequent management
Procedure details
Total ESD time, mean ± SD (min) 108.2 ± 47.3
Application time for CMC sheet, mean ± SD (min) 12.6 ± 4.0
Number of CMC sheet used for each patient, mean 1
Number of patients with visible CMC matrix after 1 week, n (%) 3 (42.9)
Adverse events
Patients developing a stricture after ESD, n (%) 4 (57.1)
Time to stricture occurrence, mean ± SD (days) 28.0 ± 3.5
Sessions of EBD required, mean ± SD, n 2.8 ± 2.2
Major intra/post-operative adverse events, n 0
SD standard deviation, ESD endoscopic submucosal dissection, CMC carboxymethyl cellulose, EBD
endoscopic balloon dilatation
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from 6 to 32 among cases without any medical intervention
after ESD) [12, 14, 29].
CMC sheet demonstrated rapid dissolution and adher-
ence onto the mucosal defect (within 1–2 min) after
exposure to its moist surface, thus avoiding the need to
use extra material (such as clips or fibrin glue) to secure
sheet attachment. Once the sheet was dissolved, it formed
a sturdy protective barrier which sealed the mucosal
defect firmly even though the defect surface was uneven.
Unlike the skin, the esophageal epithelial surface is con-
stantly exposed to food, saliva and gastric juice, which
may hinder further healing [8]. Thus, the barrier isolates
the mucosal defect from those negative impacts for at
least 1 week after ESD. However, not all of our patients
had endoscopically visible CMC matrix after 1 week. In
our opinion, the passage of food boluses and esophageal
peristalsis would have certain detrimental effects on the
sheet adherence. Another advantage was the transparency
of matrix formation once the sheet was exposed to the
mucosal defect. This did not obscure the view of the
underlying mucosal defect if requiring further endoscopic
intervention. It then takes approximately 7–14 days for
complete absorption of the sheet via hydrolysis. As
mentioned before, previous clinical trials have shown the
superior capability of CMC sheet in wound healing and
scar inhibition [19–23]. Our study was able to demon-
strate the efficacy of the sheet by reviewing the scar
formation of our patients in subsequent post-ESD endo-
scopies (Fig. 4a–h).
There were a few limitations in our study. First of all,
the number of subjects may be too small to produce any
significant result and it was not compared to a control
group. Thus, a randomized controlled study involving a
larger number of patients and the assignment of a control
group will be desirable to demonstrate the efficacy of CMC
sheet. Secondly, the effect and mechanism of CMC sheet in
preventing post-ESD esophageal stricture are still not clear,
although current data show the benefit of its application in
other organs in reducing scar formation and enhancing the
healing process [20–23]. Furthermore, the safety profile of
CMC sheet for its use in ESD still requires thorough
exploration, although no major adverse events were
reported in our study.
Conclusion
In summary, the use of CMC sheet shows great potential
for reducing the incidence of esophageal stricture follow-
ing ESD and also the number of sessions of EBD required
post-ESD. Considering the safety profile relating to other
previous methods of stricture prevention, this safe, cheap
and simple technique may have great clinical value.
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Fig. 4 Evolution of mucosal defect post-ESD and CMC application
from a study patient. a Suspicious mucosal erosions under bright light
endoscopic view. b An extensive early esophageal neoplasm revealed
after using chromoendoscopy and iodine staining. c Full circumfer-
ential esophageal mucosal defect immediately after ESD.
d Esophageal neoplasm was removed en bloc. e Mucosal defect
immediately after the application of CMC sheets. f Mucosal defect
1 week post-ESD showing residual CMC matrix. g Mucosal defect
4 weeks post-ESD showing satisfactory wound healing with minimal
scar tissue and stricture formation. h Mucosal defect was completely
healed 2 months post-ESD with minimal narrowing
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